US EditionINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta ...
NEW YORK, UNITED STATES, JUN 27 – The lawsuit alleges Sarepta Therapeutics concealed significant safety risks and trial failures of ELEVIDYS, causing investor losses during a two-year period, Rosen Law Firm said.
- Rosen Law Firm has initiated a class action lawsuit representing investors who bought securities of Sarepta Therapeutics, Inc. during the period starting from late June 2023 through mid-2025.
- The lawsuit claims that Sarepta failed to disclose significant safety concerns associated with ELEVIDYS and that the trial protocols did not identify serious side effects, resulting in defendants providing materially inaccurate or unsupported positive statements.
- Sarepta suspended enrollment and treatment in ELEVIDYS studies due to serious adverse events, leading to increased regulatory attention and heightened risks concerning the therapy’s existing and prospective approvals.
- Investors suffered damages when the true information became public, and the lead plaintiff deadline for this case is August 25, 2025.
- Rosen Law Firm, recognized for securing over $438 million for investors in 2019, encourages affected purchasers to seek compensation through contingency fee arrangements without out-of-pocket costs.
Insights by Ground AI
Does this summary seem wrong?
111 Articles
111 Articles
Coverage Details
Total News Sources111
Leaning Left17Leaning Right8Center34Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 29%
C 58%
14%
Factuality
To view factuality data please Upgrade to Premium
